OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form.

about

OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form.

Item

http://www.wikidata.org/entity/Q42396049

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form.

@en

OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form.

@nl

type

Item

label

OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form.

@en

OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form.

@nl

prefLabel

OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form.

@en

OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form.

@nl

P1476

OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form.

@en

P2093

Erica L Wegrzyn

http://www.w3.org/2001/XMLSchema#string

Jeffrey Fudin

http://www.w3.org/2001/XMLSchema#string

Mena Raouf

http://www.w3.org/2001/XMLSchema#string

P2860

Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia.

Opioid pseudoaddiction--an iatrogenic syndrome.

Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.

Sustained-release oxycodone dosing survey of chronic pain patients.

Genetics and variability in opioid response.

Opioids and the control of respiration.

Mu opioids and their receptors: evolution of a concept.

A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs

The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study.

Immediate- or sustained-release morphine for dose finding during start of morphine to cancer patients: a randomized, double-blind trial.

P304

609-612

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.2147/JPR.S117219

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27660487

http://www.w3.org/2001/XMLSchema#string

P932

5019471

http://www.w3.org/2001/XMLSchema#string